 |
|
|
| |
IBALIZUMAB: 96-WEEK DATA AND EFFICACY IN PATIENTS RESISTANT TO COMMON ANTIRETROVIRALS
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
B. EMU1, J. LALEZARI2, P. KUMAR3, S.WEINHEIMER4, S. LEWIS4, B. CASH5, Z. MIAO6, Z. COHEN6
1Yale School of Medicine, New Haven, CT, 2Quest Clinical Research, San Francisco, CA, 3Georgetown University Medical Center, Washington, DC, 4TaiMed Biologics, Irvine, CA, 5Syneos Health, Somerset, NJ, 6Theratechnologies, Montréal, Canada
|
| |
|
|
|
|
|
